Last reviewed · How we verify

NCT06798415

Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

Recruiting now Phase 2 Last updated 14 February 2025
What this trial tests

Phase 2 trial testing Metronidazole in Cutaneous Leishmaniasis in 40 participants. Currently enrolling.

Timeline
10 February 2025
Primary endpoint
1 May 2025
1 May 2025

Quick facts

Lead sponsorHayder Adnan Fawzi
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date10 February 2025
Primary completion1 May 2025
Estimated completion1 May 2025
Sites1 location across Iraq

Drugs / interventions tested

Conditions studied

Sponsor

Hayder Adnan Fawzi

Who can join

Adults 18 to 80, any sex, with Cutaneous Leishmaniasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of the study to evaluate the effectiveness of intralesional metronidazole 0.5% solution as a local injection in treating cutaneous leishmaniasis. In an open-label single-arm clinical trial, all patients will be given intralesional levofloxacin injections; the patients had cutaneous leishmaniasis lesions. Each lesion will be considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured. Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients will be only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Metronidazole

Trials testing the same drug.

Other recruiting trials for Cutaneous Leishmaniasis

Currently open trials in the same condition.

Other Hayder Adnan Fawzi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06798415.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing